Significance of molecular marker-positive cells after autologous peripheral-blood stem-cell transplantation for non-Hodgkin's lymphoma.

Hardingham, Jennifer E.; Kotasek, Dusan; Sage, Robert; Gooley, L. Terence; Mi, J X; Dobrovic, Alexander; Norman, John; Bolton, A.E.; Dale, B.M.

doi:10.1200/jco.1995.13.5.1073

Cited by 59 publications

(41 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Gribben et al (1994) report that the reappearance of circulating positive cells is strongly associated with relapse after myeloablative therapy. Similar results are shown by Hardingham et al (1995). Recently, 50-70% of cases with peripheral blood clearance have been reported after non-myeloablative therapy, both in responders and in non-responders (Betticher et al, 1996;Cabanillas et al, 1996).…”

Section: Resultssupporting

confidence: 71%

Clinical relevance of bcl-2(MBR)/JH rearrangement detected by polymerase chain reaction in the peripheral blood of patients with follicular lymphoma

Bertoni

Bosshard²,

Ricevuto³

et al. 1997

Br J Cancer

View full text Add to dashboard Cite

Summary We evaluated the prognostic role of peripheral blood polymerase chain reaction (PCR) assay for detection of the bcl-2(MBR)/JH rearrangement in 59 patients with follicular lymphoma (FL) treated at our centre since 1989. Thirty-five (59%) patients were bcl-2/JH positive and 24 (41%) were negative in the peripheral blood at diagnosis. Peripheral blood bcl-2/JH rearrangement detection at diagnosis had no relation to overall survival (OS) and time to progression (TTP). Peripheral blood PCR assay was performed post treatment in 17 patients who were bcl-2/JH positive at diagnosis. Fourteen of the patients (82%, 95% Cl 56-96%) became bcl-2/JH negative. Nine of these patients were further analysed during follow-up and, after several months, circulating cells carrying the bcl-2/JH rearrangement reappeared in five of the nine patients. Peripheral blood clearance of bcl-2/JH-positive cells was correlated with better overall survival (log-rank P < 0.05) but not with TTP.Our data confirmed that bcl-2(MBR)/JH rearrangement detection by PCR at diagnosis is not a prognostic factor in follicular lymphoma. In our series, clearance of circulating bcl-2/JH-positive cells appeared to correlate with better overall survival. Post-treatment examination of the peripheral blood by PCR may have clinical relevance for prediction of the survival pattern of the patients.

show abstract

Section: Resultssupporting

confidence: 71%

Clinical relevance of bcl-2(MBR)/JH rearrangement detected by polymerase chain reaction in the peripheral blood of patients with follicular lymphoma

Bertoni

Bosshard²,

Ricevuto³

et al. 1997

Br J Cancer

View full text Add to dashboard Cite

show abstract

“…If it would be possible to predict disease control after first-line therapy, these therapies could be selected for patients with a high likelihood of early relapse. With qualitative PCR, several studies were able to document a relationship between molecular response and time to relapse in patients treated with standard-dose chemotherapy [4,5,26], with high-dose chemotherapy [7,[27][28][29][30] and with rituximab-containing regimen [8,31,32]. Due to the low number of patients and the limited follow-up time of 6 months, we can only speculate on the role of molecular diagnostics for the prediction of relapsed disease.…”

Section: Discussionmentioning

confidence: 99%

Commercial LightCycler®-based quantitative real-time PCR compared to nested PCR for monitoring of Bcl-2/IgH rearrangement in patients with follicular lymphoma

Kornacker

Schmitt

et al. 2008

Ann Hematol

View full text Add to dashboard Cite

“…It will probably be difficult to alter the outcome of ASCT-refractory patients, that is, those with overt disease progression soon after transplant. However, the identification of patients in a minimal disease state, as some studies suggest is possible, [45][46][47] may allow the introduction of novel post transplant nonmyelosuppressive therapy, such as monoclonal antibodies and adoptive cellular therapy, that may eradicate residual disease and thereby prevent late relapses. Therefore, in addition to the development of novel agents and modalities to treat patients with overt disease progression after ASCT failure, efforts should be directed at assessing the utility and feasibility of detecting and treating ASCT failure early, in a minimal residual disease state.…”

Section: Discussionmentioning

confidence: 99%

Progressive disease following autologous transplantation in patients with chemosensitive relapsed or primary refractory Hodgkin's disease or aggressive non-Hodgkin's lymphoma

Kewalramani

Nimer

Zelenetz

et al. 2003

Bone Marrow Transplant

106

View full text Add to dashboard Cite

Summary:To determine the outcome of patients with chemosensitive relapsed or primary refractory Hodgkin's disease (HD) or aggressive non-Hodgkin's lymphoma (NHL) whose disease progresses after autologous stem cell transplantation (ASCT), we reviewed the records of 82 patients with HD and 139 patients with NHL transplanted between 1993 and 2000. Disease progression occurred in 25 patients with HD and 66 patients with NHL, with median times to progression (TTP) of 3.8 and 5.1 months, respectively. Median survival times following ASCT failure were 26 and 7.7 months for patients with HD and NHL, respectively. The second-line international prognostic index (sIPI) and the TTP (before or after 3 months from ASCT) independently were predictive of survival for NHL patients. In addition, treatment with rituximab for patients with B cell NHL was associated with improved survival (median 28.6 vs 4.1 months, P ¼ 0.003), independent of the sIPI and TTP. Prognostic factors for patients with HD were not identified. Only two patients, one of whom was among six patients who received second autologous transplants, remain disease-free. The uniformly poor outcome associated with disease progression after ASCT should prompt efforts to assess the feasibility and utility of detecting and treating post transplant residual disease during a minimal disease state, before overt progression.

show abstract

Significance of molecular marker-positive cells after autologous peripheral-blood stem-cell transplantation for non-Hodgkin's lymphoma.

Abstract: The results show that the reappearance or persistence of marker-positive cells after autologous PBSCT is strongly associated with relapse.

Cited by 59 publications

References 24 publications

Clinical relevance of bcl-2(MBR)/JH rearrangement detected by polymerase chain reaction in the peripheral blood of patients with follicular lymphoma

Clinical relevance of bcl-2(MBR)/JH rearrangement detected by polymerase chain reaction in the peripheral blood of patients with follicular lymphoma

Commercial LightCycler®-based quantitative real-time PCR compared to nested PCR for monitoring of Bcl-2/IgH rearrangement in patients with follicular lymphoma

Progressive disease following autologous transplantation in patients with chemosensitive relapsed or primary refractory Hodgkin's disease or aggressive non-Hodgkin's lymphoma

Contact Info

Product

Resources

About